Home Drug Guide Menotropins

Drug Guide

Generic Name

Menotropins

Brand Names Pergonal, Humegon, Repronex, Menopur

Classification

Therapeutic: Infertility agent

Pharmacological: Gonadotropin

FDA Approved Indications

Treatment of infertility in women with ovulatory dysfunction
Controlled ovarian hyperstimulation for IVF

Mechanism of Action

Menotropins contain both FSH and LH, which stimulate the development of ovarian follicles and induce ovulation.

Dosage and Administration

Adult: Dose varies based on indication and response; typically, starting doses range from 75-150 IU daily, adjusted based on ovarian response.

Pediatric: Not indicated for pediatric use.

Geriatric: Use not generally recommended due to limited experience; monitor closely if used.

Renal Impairment: Adjustments not well established; use with caution.

Hepatic Impairment: Use with caution; limited data.

Pharmacokinetics

Absorption: Intramuscular or subcutaneous administration, absorption varies.

Distribution: Distributed in extracellular fluids.

Metabolism: Metabolized in the liver and other tissues.

Excretion: Excreted via urine.

Half Life: Approximately 4-8 hours, varies depending on formulation and route.

Contraindications

Pregnancy (except for pregnancy induction)
Ovarian cysts or ovarian enlargement of unknown etiology
Hormone-sensitive tumors

Precautions

Monitor for ovarian hyperstimulation syndrome (OHSS)
Use with caution in women with endocrine disorders or abnormal uterine bleeding.

Adverse Reactions - Common

Ovarian hyperstimulation syndrome (OHSS) (Rare but serious)
Multiple pregnancies (Increased risk)
Pain at injection site (Common)

Adverse Reactions - Serious

Ovarian torsion or rupture (Rare)
Thromboembolic events (Rare)
Allergic reactions (Rare)

Drug-Drug Interactions

Androgens, corticosteroids (may affect ovarian response)
GnRH agonists or antagonists (used in assisted reproduction protocols)

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Assessment: Monitor ovarian response via ultrasound and hormone levels.

Diagnoses:

Risk for ovarian hyperstimulation syndrome
Risk for multiple pregnancies

Implementation: Administer as prescribed, monitor for side effects, educate patient on signs of complications.

Evaluation: Assess follicular development and ovulation response.

Patient/Family Teaching

Report severe abdominal pain, nausea, vomiting, or swelling.
Inform about the signs and risks of OHSS and multiple pregnancies.
Advise on proper injection technique and schedule.

Special Considerations

Black Box Warnings:

Multiple pregnancies and ovarian hyperstimulation syndrome (high risk with gonadotropins)

Genetic Factors: Genetic factors can influence ovarian response.

Lab Test Interference: May affect hormone levels; interpret tests accordingly.

Overdose Management

Signs/Symptoms: Severe ovarian hyperstimulation, abdominal pain, nausea, vomiting.

Treatment: Discontinue drug, provide supportive care, manage OHSS, hospitalization if necessary.

Storage and Handling

Storage: Refrigerate, protected from light.

Stability: Vial stability varies; check manufacturer information.